X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4421) 4421
female (2763) 2763
triazoles - therapeutic use (2552) 2552
male (2189) 2189
triazoles - adverse effects (2111) 2111
middle aged (1805) 1805
adult (1645) 1645
triazoles - administration & dosage (1440) 1440
aged (1116) 1116
treatment outcome (1067) 1067
pharmacology & pharmacy (1044) 1044
voriconazole (950) 950
triazoles - pharmacology (932) 932
animals (862) 862
antifungal agents - therapeutic use (844) 844
oncology (755) 755
breast neoplasms - drug therapy (722) 722
nitriles - therapeutic use (695) 695
triazoles - pharmacokinetics (613) 613
adolescent (586) 586
antifungal agents - adverse effects (584) 584
nitriles - adverse effects (555) 555
triazoles (548) 548
therapy (509) 509
care and treatment (496) 496
safety (480) 480
antifungal agents - administration & dosage (474) 474
breast cancer (474) 474
double-blind method (467) 467
drug therapy (466) 466
pyrimidines - therapeutic use (464) 464
pharmacokinetics (462) 462
infectious diseases (443) 443
dose-response relationship, drug (440) 440
efficacy (434) 434
young adult (432) 432
drug therapy, combination (425) 425
letrozole (411) 411
sitagliptin phosphate (410) 410
analysis (407) 407
tamoxifen (405) 405
administration, oral (389) 389
nitriles - administration & dosage (389) 389
medicine & public health (382) 382
research (379) 379
cancer (375) 375
postmenopausal women (374) 374
aged, 80 and over (366) 366
pyrimidines - adverse effects (362) 362
aromatase inhibitors (360) 360
anastrozole (356) 356
drug interactions (354) 354
child (350) 350
health aspects (350) 350
double-blind (348) 348
microbiology (346) 346
antifungal agents (340) 340
diabetes mellitus, type 2 - drug therapy (331) 331
hematology (325) 325
postmenopause (317) 317
aromatase inhibitors - therapeutic use (314) 314
posaconazole (312) 312
antineoplastic agents, hormonal - therapeutic use (299) 299
fluconazole (295) 295
retrospective studies (292) 292
internal medicine (290) 290
mice (288) 288
antifungal agents - pharmacokinetics (287) 287
drug administration schedule (287) 287
mycoses - drug therapy (287) 287
time factors (287) 287
medicine, general & internal (285) 285
clinical trials (283) 283
mycoses (282) 282
immunology (274) 274
rats (274) 274
aspergillosis (273) 273
pyrazines - therapeutic use (266) 266
aromatase inhibitors - adverse effects (265) 265
itraconazole (264) 264
pyrimidines - administration & dosage (263) 263
aspergillosis - drug therapy (257) 257
amphotericin-b (252) 252
endocrinology & metabolism (251) 251
risk factors (251) 251
tamoxifen - therapeutic use (249) 249
randomized controlled trials as topic (247) 247
breast neoplasms - pathology (243) 243
toxicology (240) 240
transplantation (240) 240
prospective studies (231) 231
clinical trials as topic (229) 229
benzoates - therapeutic use (224) 224
antineoplastic agents, hormonal - adverse effects (223) 223
pharmacology (221) 221
hypoglycemic agents - therapeutic use (220) 220
chemotherapy (216) 216
chemotherapy, adjuvant (212) 212
iron chelating agents - therapeutic use (209) 209
randomized-trial (208) 208
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5097) 5097
Japanese (59) 59
German (56) 56
Spanish (41) 41
French (37) 37
Chinese (10) 10
Italian (10) 10
Russian (9) 9
Dutch (7) 7
Hungarian (5) 5
Polish (2) 2
Portuguese (2) 2
Swedish (2) 2
Czech (1) 1
Danish (1) 1
Norwegian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10047, pp. 881 - 890
Summary Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological... 
Internal Medicine | TRIALS | MEDICINE, GENERAL & INTERNAL | ACCEPTABILITY | MENTAL-HEALTH-CARE | TRENDS | GUIDELINES | Mianserin - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Citalopram - adverse effects | Sertraline - adverse effects | Venlafaxine Hydrochloride - adverse effects | Imipramine - administration & dosage | Paroxetine - adverse effects | Mianserin - analogs & derivatives | Paroxetine - administration & dosage | Desipramine - adverse effects | Nortriptyline - administration & dosage | Nortriptyline - adverse effects | Mianserin - administration & dosage | Child | Fluoxetine - adverse effects | Depressive Disorder, Major - drug therapy | Clomipramine - administration & dosage | Duloxetine Hydrochloride - adverse effects | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Clomipramine - adverse effects | Evidence-Based Medicine | Desipramine - administration & dosage | Randomized Controlled Trials as Topic | Venlafaxine Hydrochloride - administration & dosage | Citalopram - administration & dosage | Confounding Factors (Epidemiology) | Sertraline - administration & dosage | Adolescent | Amitriptyline - adverse effects | Bayes Theorem | Fluoxetine - administration & dosage | Duloxetine Hydrochloride - administration & dosage | Antidepressive Agents - administration & dosage | Antidepressive Agents - adverse effects | Research Design | Amitriptyline - administration & dosage | Imipramine - adverse effects | Psychological aspects | Medical colleges | Neurosciences | Drugs and youth | Rankings | Comparative analysis | Child psychopathology | Major depressive disorder | Antidepressants, Tricyclic | Pediatric pharmacology | Mental illness | Studies | Teenagers | Mental depression | Antidepressants | Meta-analysis | Children & youth
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Antimicrobial agents and chemotherapy, ISSN 1098-6596, 2012, Volume 56, Issue 9, pp. 4793 - 4799
Journal Article
Journal of NeuroVirology, ISSN 1355-0284, 12/2017, Volume 23, Issue 6, pp. 795 - 807
..., and as such can affect neuronal function, the objective of this study was to assess the effects of ARV with high CPE... 
Neurology | Antiretrovirals | Neurosciences | Neurotoxicity | Synaptic mitochondria | Biomedicine | Immunology | Bioenergetics | Infectious Diseases | Virology | SPARE RESPIRATORY CAPACITY | CELLS | OXIDATIVE STRESS | TOXICITY | HUMAN-IMMUNODEFICIENCY-VIRUS | NEUROSCIENCES | NEUROCOGNITIVE DISORDER | INHIBITION | VIROLOGY | MITOCHONDRIAL COMPLEX-I | EFAVIRENZ | DYSFUNCTION | Raltegravir Potassium - adverse effects | Neurons - pathology | Triazoles - adverse effects | Presynaptic Terminals - pathology | Rats, Long-Evans | Cerebral Cortex - pathology | Male | Adenosine Triphosphate - biosynthesis | Nevirapine - adverse effects | Corpus Striatum - metabolism | Cerebral Cortex - metabolism | Dose-Response Relationship, Drug | Oxidative Phosphorylation - drug effects | Adenosine Triphosphate - antagonists & inhibitors | Cyclohexanes - adverse effects | Dideoxynucleosides - adverse effects | Neurons - metabolism | Cerebral Cortex - drug effects | Neurons - drug effects | Corpus Striatum - pathology | Emtricitabine - adverse effects | Presynaptic Terminals - drug effects | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Rats | Benzoxazines - adverse effects | Mitochondria - metabolism | Mitochondria - drug effects | Permeability | Animals | Corpus Striatum - drug effects | Presynaptic Terminals - metabolism | Darunavir - adverse effects | Lopinavir - adverse effects | neurotoxicity | antiretrovirals | bioenergetics | synaptic mitochondria
Journal Article
Journal Article
Diabetologia, ISSN 1432-0428, 2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose
Journal Article
Diabetes technology & therapeutics, ISSN 1557-8593, 2011, Volume 13, Issue 11, pp. 1145 - 1154
... intestinal L-cells in response to nutrient ingestion. (1) GLP-1 is responsible, in part, for the so-called incretin effect (i.e., the augmented insulin response to oral... 
Reviews | GLYCEMIC CONTROL | EFFICACY | INJECTION | ENDOCRINOLOGY & METABOLISM | SAFETY DATA | BIPOLAR I DISORDER | RANDOMIZED-TRIAL | OPEN-LABEL | RISPERIDONE | EXTENDED-RELEASE | PEPTIDE-1 ANALOG | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Peptides - pharmacokinetics | Polyglycolic Acid - adverse effects | Pyrazines - administration & dosage | Thiazolidinediones - administration & dosage | Peptides - administration & dosage | Capsules | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Venoms - administration & dosage | Adult | Polyglycolic Acid - metabolism | Sitagliptin Phosphate | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Venoms - adverse effects | Lactic Acid - metabolism | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Insulin Glargine | Pyrazines - adverse effects | Lactic Acid - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Venoms - pharmacokinetics | Type 2 diabetes | Drugs | Drug delivery systems | Forecasts and trends | Drug therapy | Vehicles
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 20, pp. 1925 - 1936
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 07/2014, Volume 132, Issue 7, pp. 832 - 837
IMPORTANCE: Optisol-GS, the most common corneal storage medium in the United States, contains antibacterial but no antifungal supplementation. Most... 
VORICONAZOLE | PRESERVATION MEDIUM | DONOR CORNEAS | RIM CULTURES | PENETRATING KERATOPLASTY | ENDOTHELIAL-CELLS | SUSCEPTIBILITY | OPHTHALMOLOGY | FUNGAL ENDOPHTHALMITIS | EYE-BANKING | TRANSPLANTATION | Dextrans - adverse effects | Triazoles - adverse effects | Antifungal Agents - adverse effects | Cornea | Cell Count | Humans | Organ Preservation | Culture Media, Serum-Free - adverse effects | Drug Contamination - prevention & control | Colony Count, Microbial | Endothelium, Corneal - pathology | Candidiasis - microbiology | Microbial Sensitivity Tests | Candidiasis - prevention & control | Candida albicans - drug effects | Chondroitin Sulfates - adverse effects | Complex Mixtures - pharmacology | Endothelium, Corneal - microbiology | Dextrans - pharmacology | Gentamicins - pharmacology | Voriconazole | Culture Media, Serum-Free - pharmacology | Antifungal Agents - pharmacology | Organ Preservation Solutions - adverse effects | Gentamicins - adverse effects | Amphotericin B - pharmacology | Treatment Outcome | Chondroitin Sulfates - pharmacology | Organ Preservation Solutions - pharmacology | Endothelium, Corneal - drug effects | Pyrimidines - pharmacology | Complex Mixtures - adverse effects | Amphotericin B - adverse effects | Triazoles - pharmacology | Pyrimidines - adverse effects | Tissue Donors | Drug Combinations | Candida glabrata - drug effects | Care and treatment | Keratitis | Amphotericin B | Endophthalmitis | Dosage and administration | Diagnosis | Research | Risk factors | Fungal antigens
Journal Article
Journal Article